CD274 and neoplasm: High PD-L1 expression on tumor cells and tumor-infiltrating immune cells is a predictor for improving atezolizumab response in NSCLC 20, and atezolizumab also exhibited a durable activity in locally advanced and metastatic urothelial carcinoma patients with higher PD-L1 expression on immune cells 21.